Co-Target(s) Information

Content Navigation (  All   None )                                      
Target General Information
Co-Targets of This Target
References
Target General Information  Top
Target ID T53601 Target Info
Target Name Bacterial 50S ribosomal RNA (Bact 50S rRNA)
Target Type Successful Target
Gene Name NO-GeName
UniProt ID
NOUNIPROTAC
Co-Targets of This Target  Top
Co-Target Name Cytochrome P450 3A (CYP3A) Successful Target
UniProt ID CP3A4_HUMAN; CP3A5_HUMAN; CP3A7_HUMAN; CP343_HUMAN
Gene Name NO-GeName
Representative Drug(s) Telithromycin Drug Info Ki = 2.4 nM [1]
Co-Target Name Voltage-gated potassium channel Kv11.1 (KCNH2) Successful Target
UniProt ID KCNH2_HUMAN
Gene Name KCNH2
Synonyms
hERG1; hERG-1; Voltage-gated potassium channel subunit Kv11.1; Potassium voltage-gated channel subfamily H member 2; HERG K+ channel; HERG; H-ERG; Ether-a-go-go-related protein 1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go related protein 1; Ether-a-go-go related gene potassium channel 1; Eag related protein 1; Eag homolog; ERG-1; ERG
    Click to Show/Hide
Representative Drug(s) Erythromycin Drug Info IC50 = 39 nM [2]
Co-Target Name Motilin receptor (MLNR) Clinical trial Target
UniProt ID MTLR_HUMAN
Gene Name MLNR
Synonyms
MLNR; Gprotein coupled receptor 38
    Click to Show/Hide
Representative Drug(s) Erythromycin Drug Info IC50 = 43.65 nM [3]
Co-Target Name Albendazole monooxygenase (CYP3A4) Clinical trial Target
UniProt ID CP3A4_HUMAN
Gene Name CYP3A4
Synonyms
Taurochenodeoxycholate 6-alpha-hydroxylase; Quinine 3-monooxygenase; P450-PCN1; Nifedipine oxidase; NF-25; HLp; Cytochrome P450-PCN1; Cytochrome P450 NF-25; Cytochrome P450 HLp; Cytochrome P450 3A4; Cytochrome P450 3A3; CYPIIIA4; CYPIIIA3; CYP3A3; Albendazole sulfoxidase; Albendazole monooxygenase (sulfoxide-forming); 1,8-cineole 2-exo-monooxygenase
    Click to Show/Hide
Representative Drug(s) Erythromycin Drug Info IC50 = 190 nM [4]
References  Top
REF 1 Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections. J Med Chem. 2009 Dec 10;52(23):7446-57.
REF 2 Structure-activity relationships of 9-substituted-9-dihydroerythromycin-based motilin agonists: optimizing for potency and safety. J Med Chem. 2009 Nov 12;52(21):6851-9.
REF 3 Macrolide-type motilin receptor agonists: Acid-stable 12-O-methyl-8,9-anhydroerythromycin A 6,9-hemiacetals. Bioorg Med Chem Lett. 1995 Apr 20;5(8):835-8.
REF 4 Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate. J Med Chem. 2009 Feb 26;52(4):1180-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.